ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AGEN Agenus Inc

10.78
0.00 (0.00%)
Pre Market
Last Updated: 10:25:05
Delayed by 15 minutes
Share Name Share Symbol Market Type
Agenus Inc NASDAQ:AGEN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 10.78 9.09 11.00 0 10:25:05

Agenus to Host Annual Meeting of Stockholders

13/06/2019 8:48pm

PR Newswire (US)


Agenus (NASDAQ:AGEN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Agenus Charts.

LEXINGTON, Mass., June 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, invites investors and the general public to attend its annual meeting of stockholders on June 19, 2019 at 5:00 p.m. ET. The meeting will be held at the Company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees will start at 4:30 p.m. ET.

Agenus Logo

Conference Call and Webcast Information:
Date: Wednesday, June 19, 2019
Time: 5:00 p.m. ET
Domestic Dial-in Number: 1-844-492-3727
International Dial-in Number: 1-412-317-5118
Conference ID: Agenus

Live Webcast: accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts or with this link https://www.webcaster4.com/Webcast/Page/1556/30853  

A replay will be available on the Company's website approximately two hours after the call and will remain available for 90 days.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Contact:

Agenus Inc. 
Jennifer Buell, PhD
781-674-4420 
Jennifer.Buell@agenusbio.com

1Through AgenTus Therapeutics, a subsidiary of Agenus

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/agenus-to-host-annual-meeting-of-stockholders-300867503.html

SOURCE Agenus Inc.

Copyright 2019 PR Newswire

1 Year Agenus Chart

1 Year Agenus Chart

1 Month Agenus Chart

1 Month Agenus Chart

Your Recent History

Delayed Upgrade Clock